Literature DB >> 31676542

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.

Nabil F Saba1, Zhuo Gerogia Chen2, Missak Haigentz3, Paolo Bossi4, Alessandra Rinaldo5, Juan P Rodrigo6, Antti A Mäkitie7, Robert P Takes8, Primoz Strojan9, Jan B Vermorken10, Alfio Ferlito11.   

Abstract

Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31676542      PMCID： PMC6830522          DOI： 10.1158/1535-7163.MCT-19-0214

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


  85 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Authors:  S M Huang; J M Bock; P M Harari
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

Review 3.  The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.

Authors:  Dan P Zandberg; Scott E Strome
Journal:  Oral Oncol       Date:  2014-05-10       Impact factor: 5.337

4.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

Authors:  T Kawamoto; J D Sato; A Le; J Polikoff; G H Sato; J Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

5.  Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Authors:  Tanja Schneider-Merck; Jeroen J Lammerts van Bueren; Sven Berger; Kai Rossen; Patrick H C van Berkel; Stefanie Derer; Thomas Beyer; Stefan Lohse; Wim K Bleeker; Matthias Peipp; Paul W H I Parren; Jan G J van de Winkel; Thomas Valerius; Michael Dechant
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

6.  Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Authors:  Ning Jiang; Dongsheng Wang; Zhongliang Hu; Hyung Ju C Shin; Guoqing Qian; Mohammad Aminur Rahman; Hongzheng Zhang; A R M Ruhul Amin; Sreenivas Nannapaneni; Xiaojing Wang; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Jun Ma; Zhuo G Chen; Nabil F Saba
Journal:  Mol Cancer Ther       Date:  2014-04-18       Impact factor: 6.261

7.  Nuclear EGFR contributes to acquired resistance to cetuximab.

Authors:  C Li; M Iida; E F Dunn; A J Ghia; D L Wheeler
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867

8.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Authors:  David S Shames; Juliet Carbon; Kim Walter; Adrian M Jubb; Cleopatra Kozlowski; Tom Januario; An Do; Ling Fu; Yuanyuan Xiao; Rajiv Raja; Brittany Jiang; Ashi Malekafzali; Howard Stern; Jeff Settleman; Timothy R Wilson; Garret M Hampton; Robert L Yauch; Andrea Pirzkall; Lukas C Amler
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.

Authors:  J B Vermorken; A Psyrri; R Mesía; F Peyrade; F Beier; B de Blas; I Celik; L Licitra
Journal:  Ann Oncol       Date:  2014-02-26       Impact factor: 32.976
View more
  10 in total

1.  Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer.

Authors:  Michael Mints; David Landin; Anders Näsman; Leila Mirzaie; Ramona Gabriela Ursu; Mark Zupancic; Linda Marklund; Tina Dalianis; Eva Munck-Wikland; Torbjörn Ramqvist
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

2.  A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.

Authors:  Zeng Qi; Yue Qiu; Zhaohui Wang; Huiping Zhang; Ling Lu; Yanqiu Liu; David Mathes; Elizabeth A Pomfret; Dexiang Gao; Shi-Long Lu; Zhirui Wang
Journal:  Mol Oncol       Date:  2021-02-20       Impact factor: 6.603

Review 3.  Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.

Authors:  Sandra Ortiz-Cuaran; Jebrane Bouaoud; Andy Karabajakian; Jérôme Fayette; Pierre Saintigny
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

4.  Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes.

Authors:  Maria R Jubran; Daniela Vilenski; Efrat Flashner-Abramson; Efraim Shnaider; Swetha Vasudevan; Ariel M Rubinstein; Amichay Meirovitz; Shay Sharon; David Polak; Nataly Kravchenko-Balasha
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

5.  Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.

Authors:  Liwei Lang; Fang Wang; Zhichun Ding; Xiangdong Zhao; Reid Loveless; Jin Xie; Chloe Shay; Peng Qiu; Yonggang Ke; Nabil F Saba; Yong Teng
Journal:  J Exp Clin Cancer Res       Date:  2021-12-14

6.  Efficacy and safety of transarterial chemoembolization with CalliSpheres® Microspheres in head and neck cancer.

Authors:  Fei Gao; Jinqi Gao; Kuiyang Wang; Lei Song
Journal:  Front Surg       Date:  2022-08-25

7.  Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma.

Authors:  An Song; Yuanyuan Wu; Weiming Chu; Xueming Yang; Zaiou Zhu; Enshi Yan; Wei Zhang; Junbo Zhou; Xu Ding; Jie Liu; Hongxia Zhu; Jinhai Ye; Yunong Wu; Yang Zheng; Xiaomeng Song
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

8.  Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.

Authors:  Christine H Chung; Marcelo Bonomi; Conor E Steuer; Jiannong Li; Priyanka Bhateja; Matthew Johnson; Jude Masannat; Feifei Song; Juan C Hernandez-Prera; Bruce M Wenig; Helen Molina; Joaquim M Farinhas; Caitlin P McMullen; J Trad Wadsworth; Krupal B Patel; Julie A Kish; Jameel Muzaffar; Kedar Kirtane; James W Rocco; Michael J Schell; Nabil F Saba
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

Review 9.  At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma.

Authors:  Niels E Wondergem; Dennis N L M Nijenhuis; Jos B Poell; C René Leemans; Ruud H Brakenhoff; Rieneke van de Ven
Journal:  Front Oral Health       Date:  2021-03-05

10.  Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.

Authors:  Takashi Kurosaki; Seiichiro Mitani; Kaoru Tanaka; Shinichiro Suzuki; Hiroaki Kanemura; Koji Haratani; Soichi Fumita; Tsutomu Iwasa; Hidetoshi Hayashi; Takeshi Yoshida; Kazuki Ishikawa; Mutsukazu Kitano; Naoki Otsuki; Yasumasa Nishimura; Katsumi Doi; Kazuhiko Nakagawa
Journal:  Anticancer Drugs       Date:  2021-01-01       Impact factor: 2.389
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.